In the News March 30, 2017

The Pink Sheet | Off-Label Opioid Promotion: US FDA 'Does Not Object' To Intranasal Deterrence Data, Egalet Says

Marc Scheineson comments on the U.S. Food and Drug Administration’s approval of promotional materials highlighting a drug’s novel and generic abuse-deterrent formulation.
Media Contact
Alex Wolfe
Communications Director

This website uses cookies to improve functionality and performance. For more information, see our Privacy Statement. Additional details for California consumers can be found here.